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ABSTRACT 
Background and Objectives: Placement of drug-eluting stents (DES) can be complicated by stent thrombosis; 
prophylactic antiplatelet therapy has been used to prevent such events. We evaluated the efficacy of cilostazol 
with regard to stent thrombosis as adjunctive antiplatelet therapy. Subjects and Methods: A total of 1,315 patients 
(846 males, 469 females) were prospectively enrolled and analyzed for the frequency of stent thrombosis. Patients 
with known risk factors for stent thrombosis, except diabetes and acute coronary syndrome, were excluded from 
the study. All patients maintained antiplatelet therapy for at least six months. To evaluate the effects of cilostazol 
as another option for antiplatelet therapy, triple antiplatelet therapy (aspirin+clopidogrel+cilostazol, n=502) was 
compared to dual antiplatelet therapy (aspirin+clopidogrel, n=813). Six months after stent placement, all patients 
received only two antiplatelet drugs: treatment either with cilostazol+aspirin (cilostazol group) or clopidogrel+as-
pirin (clopidogrel group). There were 1,033 patients (396 in cilostazol group and 637 in clopidogrel group) that 
maintained antiplatelet therapy for at least 12 months and were included in this study. Stent thrombosis was de-
fined and classified according to the definition reported by the Academic Research Consortium (ARC). Results: 
During follow-up (561.7±251.4 days), 15 patients (1.14%) developed stent thrombosis between day 1 to day 657. 
Stent thrombosis occurred in seven patients (1.39%) on triple antiplatelet therapy and four patients (0.49%) on 
dual antiplatelet therapy (p=NS) within the first six months after stenting. Six months and later, after stent 
implantation, one patient (0.25%) developed stent thrombosis in the cilostazol group, and three (0.47%) in the 
clopidogrel group (p=NS). Conclusion: During the first six months after DES triple antiplatelet therapy may be 
more effective than dual antiplatelet therapy for the prevention of stent thrombosis. However, after the first six 
months, dual antiplatelet treatment, with aspirin and cilostazol, may have a better cost benefit ratio for the pre-
vention of stent thrombosis. (Korean Circ J 2010;40:10-15) 
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Introduction 
 
Since Andreas Gruentzig performed the first successful 
balloon angioplasty in 1977, percutaneous coronary in-
terventions (PCI) have changed considerably. The im-
plantation of drug-eluting stents (DES) was introduced 
in 2001 and has been a popular catheter-based me-
thod used in clinical practice worldwide. The DES has 
noticeably reduced the frequency of restenosis, which 
was one of the most difficult problems associated with 
bare metal stents. Large scale studies have demonstrated 
the effectiveness of DES for reducing the frequency of 
restenosis and major cardiac events.
1-7) However, long 
term follow up studies have reported various additional 
problems such as stent thrombosis. Treatment with 
dual antiplatelet therapy has reduced the frequency of 
stent thrombosis in patients treated with DES.
8) 
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The goal of this prospective randomized trial was to 
evaluate the efficacy of the antiplatelet agent cilostazol 
for the prevention of stent thrombosis in patients with 
DES intervention.   
 
Subjects and Methods 
 
Patients that received coronary artery intervention 
using the sirolimus-eluting stent (Cypher
®, Cordis Cor-
poration, USA) and the paclitaxel-eluting stent (Taxus
®, 
Boston Scientific Corporation, USA) were prospecti-
vely enrolled from August 2006 to February 2008 at 
the Catholic University of Korea, St. Mary’s Hospital, 
St. Paul’s Hospital, Uijeongbu St. Mary’s Hosptial, Dae-
jeon St. Mary’s Hospital, St. Vincent’s Hospital, and 
Incheon St. Mary’s Hospital, all in Korea.   
Patients with factors that increased their risk for the 
development of acute or subacute stent thrombosis such 
as patients with severe calcification on fluoroscopy, bi-
furcated lesions treated with the T stent technique and 
Y stent technique, the stent cross-over technique used 
for bifurcated lesions with a side branch >2.5 mm, over-
lapping of two stents in one vessel, >20% residual ste-
nosis, dissection in the distal area of the stent, patients 
with chronic renal failure on dialysis, those with a low 
ejection fraction (<40%), and patients with severe pro-
trusion of tissues or thrombus. In addition, patients on 
anticoagulation therapy because of atrial fibrillation and 
patients that had a left main coronary artery interven-
tion were also excluded. Furthermore, patients that had 
to change antiplatelet medications during the trial due 
to complications and those that did not comply with 
taking their medication were also excluded. However, 
the interrupted use of aspirin for a procedure with the 
replacement by other antiplatelet agents temporarily was 
not an indication for exclusion. Coronary stenting was 
performed according to standard intervention techni-
ques; the final balloon angiography, the method used 
for implantation of stents, and the use of glycoprotein 
IIb/IIIa blockers were based on the operator’s decisions. 
All patients were instructed to take 100 mg aspirin 
for the rest of their lives. During the initial six months 
after the PCI, all patients received 300 mg clopidogrel 
administered as a loading dose, and 75 mg was given as 
a maintenance dose. Cilostazol, 100 mg, was given twice 
a day. The patients were divided into a triple antiplate-
let therapy group and a dual antiplatelet therapy group. 
Starting from six months after the PCI, two types of 
antiplatelet agents were administered until the com-
pletion of the study. The antiplatelet agent used in ad-
dition to aspirin, was clopidogrel or cilostazol, which 
was assigned randomly to the dual antiplatelet therapy 
group and the triple antiplatelet therapy group. The 
group that received aspirin and clopidogrel was the 
clopidogrel group, and the group that received aspirin 
and cilostazol was the cilostazol group. All patients were 
regularly followed and examined in the outpatient clinic. 
A comparison of the dual antiplatelet therapy group 
with the triple antiplatelet therapy group was perform-
ed on patients taking antiplatelet agents for longer than 
six months after stent implantation. In addition, a com-
parison of the clopidogrel group and the cilostazol group 
was performed on the patients taking antiplatelet agents 
for longer than 12 months after stent implantation. To 
resolve the problems associated with subjective defini-
tions of stent thrombosis, the Academic Research Con-
sortium (ARC), in 2007, divided stent thrombosis into 
three types: definite, probable, and possible, and based 
on the ARC the time of the occurrence; that is, from the 
intervention to the time of the onset of clinical symp-
toms, early (within 1 month), late (within 1 year), and 
very late (after 1 year) groups were defined. We used the 
definition of stent thrombosis as defined by the ARC 
criteria.
9) The study was terminated in patients that de-
veloped stent thrombosis, at the last outpatient visit, or 
without drug interruption for longer than four days. 
 
Statistics and data analysis 
All data are presented as the mean±standard error 
using Statistical Package for  the Social Sciences (SPSS) 
statistical software (SPSS, Inc, Chicago, IL, USA). For 
the comparison of categorical data in each therapy group, 
the chi-square test was applied, and for comparison of 
continuous data, the t-test was used. Cases with a p less 
than 0.05 were considered statistically significant. 
 
Results 
 
There were 1,315 patients that took antiplatelet agents 
according to the study protocol for longer than six mon-
ths. The average follow up period was 561.7±251.4 
days. The mean age of the patients was 63.4±10.8 years. 
There were 846 men (64.3%) and 469 women (35.7%). 
The patient diagnoses included: ST elevation myocar-
dial infarction in 11.2%, non-ST elevation myocardial 
infarction or unstable angina in 58.2%, and stable an-
gina in 30.6%. Stent thrombosis developed in 15 cases 
(1.14%). The onset of symptoms developed between day 
1 after the intervention and day 657; eight patients de-
veloped symptoms within 30 days (0.6%). The clinical 
characteristics of the patients that developed stent throm-
bosis and the stents used are listed in Table 1 and 2. 
Among 1,315 patients followed for six months after 
stent implantation, the dual antiplatelet therapy group 
included 813 patients, and the triple antiplatelet thera-
py group 502 patients. The comparison of the two groups 
with regard to their age, gender, clinical diagnosis and 
the risk factors for coronary artery disease showed not 
significant differences. There were 41.6% of the patients 
with multivessel disease in the triple antiplatelet therapy  
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group compared to 28.9% in the dual antiplatelet th-
erapy group (p<0.001). Comparison of the implanted 
DES in the dual antiplatelet therapy group with the 
triple antiplatelet therapy group showed that the num-
ber of stents used (1.56±0.74, 1.70±0.94, p<0.001), 
the number of Taxus® stents (0.50±0.75, 0.74±0.1, 
p<0.001), the total length of the stents (34.08±20.08 
mm, 40.16±24.03 mm, p<0.001), and the mean dia-
meter of the stents (3.24±0.56 mm, 3.16±0.48 mm, 
p<0.05) in the two groups were significantly different. 
Stent thrombosis developed in 11 cases (0.84%), and 
according to the ARC definitions, in the dual antipla-
telet therapy group there were three and one definite 
and possible cases, respectively; in the triple antiplate-
let therapy group there were one, five and one definite, 
probable, and possible cases respectively. The compa-
rison of the development of stent thrombosis according 
to treatment methods showed that the dual antiplate-
let therapy group had four cases (0.49%), the triple an-
tiplatelet therapy group had seven cases (1.39%); al-
though the tendency was higher in the triple antiplate-
let therapy group, the difference between the two groups 
was not statistically significant (Table 3). 
There were 1,033 patients that were followed for a 
minimum of 12 months, after the intervention. Accord-
ing to the method of random addition of the second 
antiplatelet agent to aspirin, the patients were divided 
into the cilostazol treatment group (n=396) and the 
clopidogrel treatment group (n=637), and subsequently 
followed for a mean of 463.9±220.4 days. Comparison 
of the two groups showed no significant differences with 
regard to their age, gender, clinical diagnosis, risk factors 
for coronary artery disease, and the distribution of mul-
tivessel disease. In addition, comparison of the implant-
ed DES, the number of stents used (1.58±0.84, 1.56±
0.85, p=NS), the number of Taxus® stents (0.51±0.57, 
0.75±0.82, p=NS), the total length of the stent (37.03 
±21.07 mm, 36.53±22.00 mm, p=NS) and the av-
erage diameter of the stent (3.20±0.58 mm, 3.20±
0.50 mm, p=NS), showed no significant differences 
between the two groups. The follow up observation pe-
riod for the clopidogrel treatment group was signifi-
cantly longer (436.0±207.4 days, 480.8±226.9 days, 
p<0.005); stent thrombosis developed in four cases 
(0.38%). According to the ARC definitions, two cases 
were probable and two cases were possible. In the cilo- 
Table 1. Clinical characteristic of patients with stent thrombosis
No. of patients  Protocol  Age (years)  Gender  Diabetes  Diagnosis  Stent thrombosis 
event (day)  ARC
01 Dual  82  M  -  STEMI  001 Definite
02 Triple  78 F  -  NSTEMI  001 Definite
03 Triple  80 M +  UA  001 Probable
04 Triple  70 F  -  UA  003 Probable
05 Dual  58 M  -  SA  005 Definite
06 Triple  79 F  +  NSTEMI  008 Probable
07 Triple  75 F  -  STEMI  010 Probable
08 Triple  66 M +  SA  011 Probable
09 Triple  71 M +  UA  082 Possible
10 Dual  57 M  -  STEMI  097 Possible
11 Dual  56 F  -  NSTEMI 135  Definite
12 Clopidogrel  70  M +  UA 240  Possible
13 Clopidogrel  76 M +  SA 250  Possible
14 Cilostazol  40  M  -  UA 619  Probable
15 Clopidogrel  50 M +  STEMI 657  Probable
Dual: aspirin+clopidogrel, Triple: aspirin+clopidogrel+cilostazol, clopidogrel: aspirin+clopidogrel, cilostazol: aspirin+cilostazol. STEMI: ST 
elevation myocardial infarction, NSTEMI: Non ST elevation myocardial infarction, UA: unstable angina, SA: stable angina, ARC: Academic 
Research Consortium 
 
Table 2. Stent characteristics of patients with stent thrombosis
No. of 
patients 
Number 
of stent 
Number of 
Taxus® 
Total stent 
length (mm) 
Average stent
diameter (mm)
01 1  0  28.00 3.00 
02 2  0  42.00 3.00 
03 1  0  28.00 3.00 
04 1  1  32.00 3.00 
05 2  0  56.00 3.00 
06  1 0 18.00 3.00 
07 2  2  56.00 3.25 
08 2  2  64.00 2.75 
09 3  0  48.75  2.91 
10 1  1  16.00 3.50 
11  1 0 18.00 3.50 
12 1  0  28.00 3.50 
13 1  0  23.00 3.00 
14 1  0  28.00 3.00 
15 1  1  16.00 3.50 
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stazol treatment group, there was 1 case (0.25%) of stent 
thrombosis, and in the clopidogrel treatment group, 
there were three cases (0.47%). No statistically signifi-
cant difference between the cilostazol treatment group 
and the clopidogrel treatment group was not detected 
for stent thrombosis (Table 4).  
Table 3. Clinical and procedural characteristics of patients in the dual therapy and triple therapy group
  Dual therapy (n=813)  Triple therapy (n=502)  p 
Age (years)  63.1±10.9 63.8±10.6 NS
Male gender (%)  64.0  64.4  NS
Diabetes (%)  31.4  33.3  NS
Hypertension (%)  55.7  57.9  NS
Current smoking (%)  30.6  29.8  NS
Total cholesterol (mg/dL)  180.4±42.1 181.1±40.6 NS
Clinical presentation (%)      NS
 STEMI  09.7 12.4   
 NSTEMI/UA  58.9  59.3   
 SA  31.4  28.3   
Multivessel disease (%)  28.9  41.6  <0.001
Stent thrombosis (%)  4 (0.49)  7 (1.39)  NS
ARC      
 Definite  3  1   
 Probable  0  5   
 Possible  1  1   
Number of stent  1.56±0.74 1.70±0.94  <0.001
Number of Taxus® 0.50±0.75 0.74±0.1  <0.001
Total stent length (mm)  34.08±20.08 40.16±24.03  <0.001
Average stent diameter (mm)  3.24±0.56 3.16±0.48  <0.05
STEMI: ST elevation myocardial infarction, NSTEMI: non ST elevation myocardial infarction, UA: unstable angina, SA: stable angina,
ARC: Academic Research Consortium 
 
Table 4. Clinical and procedural characteristics of patients in the cilostazol group and the clopidogrel group 
  Cilostazol (n=396)  Clopidogrel (n=637)  p 
Age (years)  62.9±11.2 63.2±10.5 NS
Male gender (%)  62.1  65.6  NS
Diabetes (%)  31.8  32.0 NS
Hypertension (%)  53.4  57.7  NS
Current smoking (%)  26.6  29.4  NS
Total cholesterol (mg/dL)  181.3±39.4 180.7±42.8 NS
Clinical presentation (%)      NS
 STEMI  09.1 11.1   
 NSTEMI/UA  61.7  57.7   
 SA  29.2  31.1   
Multivessel disease (%)  34.8  33.8  NS
The follow-up duration, days  436.0±207.4 480.8±226.9  <0.005
Stent thrombosis (%)  1 (0.25)  3 (0.47)  NS
ARC      
 Definite       
 Probable  1  1   
 Possible    2   
Number of stent  1.58±0.84 1.56±0.85 NS
Number of Taxus® 0.51±0.57 0.75±0.82 NS
Total stent length (mm)  37.03±21.07 36.53±22.00 NS
Average stent diameter (mm)  3.20±0.58 3.20±0.50 NS
STEMI: ST elevation myocardial infarction, NSTEMI: non ST elevation myocardial infarction, UA: unstable angina, SA: stable angina,
ARC: Academic Research Consortium    
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Discussion 
 
Since DES implantation can suppress the formation 
of the neointima following mechanical injury, it pre-
vents restenosis, which was a significant complication 
associated with bare metal stents. However, although 
stent thrombosis developing after DES implantation is 
rare,
10) in the papers presented at the 2006 European 
Society of Cardiology, and since then, the mortality 
and the incidence of myocardial infarction associated 
with DES have been reported to be higher than with 
bare metal stents, and thus there is significant concern 
about the safety of DES.
8)11-18) However, studies have 
demonstrated that the frequency of early stent throm-
bosis and late stent thrombosis in bare metal stents 
and DES are not significantly different.
19-21) However, 
the risk for very late stent thrombosis with a DES has 
been reported to be higher than with a bare metal stent. 
This was the motivation for changing the treatment 
guidelines for the duration of clopidogrel administ-
ration. For patients with DES, at the time of its appro-
val by the US food and drug administration for wide 
clinical use, the dual antiplatelet treatment of Cypher
® 
for longer than three months and of Taxus
® for longer 
than six months was recommended. However, the 2005 
treatment guidelines of the American Heart Associa-
tion/American College of Cardiology (AHA/ACC), re-
commended clopidogrel for 12 months after DES im-
plantation, and the 2007 treatment guidelines, recom-
mended treatment for a minimum of 12 months; in ad-
dition, the method of antiplatelet treatment has been 
changed.
22)  
The development of stent thrombosis could not be 
explained by one mechanism or a single causative factor. 
It has been shown that in addition to patient factors, 
numerous factors such as stent problems, problems with 
the stent implantation procedure, reactions to antipla-
telet agents, and the characteristics of the lesion are in-
volved in combination. Risk factors associated with stent 
thrombosis such as, diabetes, chronic renal failure, left 
ventricular dysfunction, in cases performed on bifur-
cated lesions or thin and long lesions, in cases where 
the stents were not dilated sufficiently and thus resi-
dual stenosis remained, or dissection have been previ-
ously reported. The AHA/ACC has stated that large 
scale studies are needed to study the risk factors associ-
ated with antiplatelet treatment and stent thrombosis 
to determine optimal patient management.   
Cilostazol is a phosphodiesterase III blocker; it is a 
drug that exerts the dual effects of suppression of th-
rombus aggregation and proliferation of the neointima. 
Lee et al.
23)24) reported that after bare metal stent im-
plantation, cilostazol has suppressive effects on the de-
velopment of thrombi in patients with high risk factors 
for developing a thrombus, such as reducing restenosis 
in patients with diabetes after DES implantation. Cilo-
stazol is an antiplatelet agent widely used after stent im-
plantation together with aspirin and clopidogrel. How-
ever, a cost benefit analysis of triple therapy, adding 
cilostazol to the standard dual therapy, has not been 
conducted. In this study, 1,315 patients were enrolled 
with an average follow up of 561.7±251.4 days. Based 
on the ARC definitions, stent thrombosis developed 
in 15 cases (1.14%). The frequency of stent thrombosis 
is different, depending on the definition of stent throm-
bosis used in a study. In studies reporting less than a 
1% frequency of stent thrombosis, the length of the 
stent and the number of stents used were significantly 
different from this study. In a study on 260 patients 
comparing triple therapy and dual therapy including 
cilostazol, after DES implantation, stent thrombosis 
occurred in 0.4% in each group, with no significant dif-
ference detected.
25) However, in these prior studies, the 
ARC definitions were not used and thus the frequency 
of stent thrombosis was reported to be somewhat lower 
then in this study. With regard to patients with diabetes, 
during 15 months of follow up after DES implantation, 
if the definitions used included: definite, probable and 
possible, the frequency increased to 2.4%.
26) Comparing 
our study with such studies, showed a lower frequency 
of stent thrombus in this study. In addition, we did 
not find a significant difference in the frequency of 
stent thrombosis according to dual or triple antiplate-
let treatment. Therefore, with regard to the cost bene-
fit ratio dual therapy is more cost effective than triple 
therapy. Within the first six months from the stent 
implantation, the prevention of stent thrombosis with 
the combination of aspirin and cilostazol was compar-
able to the combination of aspirin and clopidogrel. Even 
after six months, the frequency of stent thrombosis was 
lower than in previous studies. The patients in our study 
continued to take two types of antiplatelet agents even 
after six months, which may have prevented stent th-
rombosis. Further study is needed comparing mono-
therapy and combination treatments.  The limitations 
of this study include the following. Only patients with 
continuous intake of antiplatelet agents could be as-
sessed in the outpatient clinics. Therefore, for patients 
that discontinued taking antiplatelet agents intention-
ally or those that could not be assessed due to transfer 
to another hospital the study was terminated and thus 
many patients were lost. In addition, this study was an 
open label study, and the investigators were not blind 
to the treatment. In regard to the use of the ARC defi-
nitions, some deaths might not have been classified 
inappropriately; therefore, the diagnosis of stent throm-
bosis might not have been completely accurate. The tri-
ple antiplatelet therapy group, had a significantly longer 
length of the stent and the number of stents used was 
greater; this suggests that there might have been some  
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bias in assigning patients to the triple therapy treatment 
group.  
In conclusion, the results of this study showed no 
significant difference between triple and dual treatment 
groups for the prevention of stent thrombosis after DES. 
Further study is need with large randomized blinded 
trials to determine optimal antiplatelet therapy for pa-
tient undergoing stent implantation. 
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